1. 1) Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, “Good Post-marketing Surveillance Practice for re-examination application of new drugs (Yaku-hatsu No. 646),” 1991.
2. 2) Ministry of Health, Labour and Welfare (MHLW), Good Post-marketing Study Practice for drugs (MHLW Ministerial Ordinance No. 171 of 2004), 2004.
3. 3) Ministry of Health and Welfare (MHW), Good Clinical Practice for Drugs (MHW Ministerial Ordinance of No. 28 of 1997), 1997.
4. 4) Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare, “Guidance of Risk Management Planning for Pharmaceuticals (Yaku-shoku-an hatsu 0411 No.1, Yaku-shoku-shinsa hatsu 0411 No. 2, April 11, 2012),” 2012.
5. 5) Arima H., Kondo N., Tasaki M., Teramoto T., Mizui T., Watanabe T., J. Jpn. Soc. Hosp. Pharm., 52, 1234-1242 (2016).